The University of Cincinnati College of Medicine, located in Cincinnati, Ohio, represents one of the nation's premier institutions for neurodegenerative disease research and clinical care. Founded in 1819, the university is the oldest public university in Ohio and has established a distinguished legacy in neuroscience research. The College of Medicine, together with Cincinnati Children's Hospital Medical Center, forms one of the largest academic health science centers in the United States, with extensive programs in neurology, neurosurgery, and neuroscience research[1].
The university's movement disorders program is internationally recognized for its clinical care and research excellence, particularly in Parkinson's disease and atypical parkinsonian disorders. The institution's researchers have made significant contributions to understanding the molecular and cellular mechanisms underlying neurodegeneration, developing novel therapeutic approaches, and establishing best practices for patient care.
The Movement Disorders Center at the University of Cincinnati is the flagship program for research and clinical care in Parkinson's disease and related disorders. The center has been designated as a Parkinson's Foundation Center of Excellence, recognizing its comprehensive approach to patient care and its strong research program[2].
The center encompasses several major research initiatives:
The Memory Disorders Center at the University of Cincinnati investigates all aspects of Alzheimer's disease and related dementias. Research focus areas include:
The ALS program at the University of Cincinnati provides comprehensive care for patients with ALS and related disorders while conducting research to develop new treatments. Research priorities include:
Basic science research at the University of Cincinnati focuses on understanding the fundamental mechanisms of neurodegeneration:
The University of Cincinnati has been a leader in deep brain stimulation research and clinical practice. The program has performed over 1,000 DBS procedures and maintains one of the largest DBS databases in the world. Research focuses on:
Studies have demonstrated that DBS can significantly improve motor symptoms in Parkinson's disease, reduce medication requirements, and enhance quality of life. The program has contributed to establishing best practices for patient selection, surgical technique, and postoperative management[4:1].
Non-motor symptoms are a major research focus at the University of Cincinnati, as these symptoms often have the greatest impact on patient quality of life. Research includes:
Research has demonstrated that non-motor symptoms often precede motor symptoms in Parkinson's disease and can serve as early markers of neurodegeneration. Studies have also shown that non-motor symptoms are major determinants of quality of life and that they require as much attention as motor symptoms in clinical management[8].
The University of Cincinnati has particular expertise in atypical parkinsonian disorders, including progressive supranuclear palsy, multiple system atrophy, and corticobasal degeneration. Research focuses on:
Studies have demonstrated that atypical parkinsonian disorders have distinct pathological features and clinical courses compared to Parkinson's disease, and that accurate diagnosis is important for prognosis and treatment planning[3:1].
Research on alpha-synuclein at the University of Cincinnati encompasses both basic science and clinical investigations. Basic science research focuses on:
Clinical research includes:
Studies have demonstrated that alpha-synuclein can propagate between neurons in a prion-like manner, contributing to disease progression. This understanding has led to new therapeutic strategies aimed at blocking alpha-synuclein propagation[9].
The University of Cincinnati has been designated as a Parkinson's Foundation Center of Excellence, recognizing its comprehensive approach to Parkinson's disease care. The center provides:
The center follows over 1,500 patients with Parkinson's disease and related disorders, making it one of the largest Parkinson's programs in the Midwest.
The Movement Disorders Fellowship at the University of Cincinnati trains the next generation of movement disorder specialists. Fellows receive comprehensive training in:
Graduates of the program have established movement disorder programs at academic centers across the country.
The Memory Disorders Center offers comprehensive evaluation and treatment for patients with:
Services include neuropsychological testing, neuroimaging, biomarker analysis, and access to clinical trials.
The University of Cincinnati provides state-of-the-art facilities for neurodegenerative disease research:
The University of Cincinnati actively participates in clinical trials for neurodegenerative diseases:
| Condition | Intervention | Phase | Status |
|---|---|---|---|
| Parkinson's disease | Deep brain stimulation | Post-approval | Enrolling |
| Parkinson's disease | Alpha-synuclein inhibitor | Phase 2 | Active |
| Parkinson's disease | LRRK2 inhibitor | Phase 2 | Recruiting |
| Alzheimer's disease | Anti-amyloid antibody | Phase 3 | Active |
| ALS | Gene therapy | Phase 1/2 | Various |
| Progressive supranuclear palsy | Tau inhibitor | Phase 2 | Enrolling |
The University of Cincinnati has attracted leading researchers in neurodegenerative diseases:
The University of Cincinnati offers comprehensive training in neurodegenerative disease research:
The University of Cincinnati collaborates with:
As a major academic medical center in the Midwest, the University of Cincinnati serves as a regional referral center for patients with neurodegenerative diseases from Ohio, Kentucky, Indiana, and surrounding states. The institution's research programs have:
The university also serves the greater Cincinnati community, providing educational programs, support groups, and community outreach to improve awareness and care for neurodegenerative diseases.
Research conducted at the University of Cincinnati has made significant contributions to the neurodegenerative disease field:
The University of Cincinnati is committed to community education and outreach:
University of Cincinnati College of Medicine. Neurology Department Annual Research Report 2024. 2024. ↩︎
Parkinson's Foundation. Centers of Excellence Program 2024. 2024. ↩︎
Phielipp N, et al. Atypical parkinsonism: clinical features and treatment. Current Neurology Neuroscience Reports. 2017. ↩︎ ↩︎
Deuschl G, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. New England Journal of Medicine. 2006. ↩︎ ↩︎
Wong YC, Krainc D. Alpha-synuclein toxicity in neurodegeneration. Molecular Psychiatry. 2020. ↩︎
Chen JY, et al. Neuroinflammation in neurodegenerative disease. Brain. 2017. ↩︎
Postuma RB, et al. REM sleep behavior disorder as a biomarker for neurodegeneration. Nature Reviews Neurology. 2015. ↩︎
Chaudhuri KR, et al. Non-motor symptoms of Parkinson's disease. Movement Disorders. 2015. ↩︎
Volpicelli-Daley LA, et al. Alpha-synuclein aggregation and propagation. Acta Neuropathologica Communications. 2021. ↩︎